Multiple sclerosis (MS) is a disabling, chronic disease that imposes a significant economic
burden on patients and the US healthcare system. The largest cost component for …

Background: The current focus in multiple sclerosis (MS) is on early diagnosis and drug
intervention, with a view to modifying disease progression. Consequently, healthcare costs …

Background In an era of scarce resources, policy makers, neurologists and other
stakeholders need to be aware of the economic burden of multiple sclerosis and the cost …

Objective To evaluate the cost-effectiveness of alemtuzumab compared with fingolimod,
natalizumab, ocrelizumab, and generic glatiramer acetate 20 mg among patients with …

Introduction and objective Multiple sclerosis (MS) is a chronic inflammatory disease of the
central nervous system. MS is considered incurable; however, disease treatment has …

abstract Objectives To estimate health state utility values (HSUVs) for multiple sclerosis (MS)
by key demographic and clinical characteristics. Methods Data from a UK prospective …

Background For older adults with relapsing-onset multiple sclerosis (MS), limited information
is available to inform if, or when, disease-modifying drugs (DMDs) may be safely …

Background For patients with multiple sclerosis (MS), previous research identified key
disease sequelae as important cost drivers and suggested that among users of disease …

Background Numerous cost-effectiveness analyses (CEAs) of disease-modifying therapies
(DMTs) for relapsing–remitting multiple sclerosis (RRMS) have been published in the last …

Background Relapses can have a major impact on the lives of people with multiple sclerosis
(MS), and yet relapse-related healthcare costs have received little attention. This has limited …